JournalPatents

Section 3(d) for pharma researchers: when a new form of a known drug is patentable

Section 3(d) of the Patents Act explained for pharma faculty: when a salt, polymorph or new form of a known drug is patentable and what efficacy data to show.

By Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP 7 min read
Short answer

Section 3(d) of the Patents Act, 1970 bars patents on a mere new form of a known substance unless it enhances the substance's known efficacy. Its Explanation treats salts, esters, polymorphs, isomers and other derivatives as the same substance unless they differ significantly in efficacy. For medicines, the Supreme Court held in Novartis (2013) that efficacy means therapeutic efficacy.

Many pharmaceutical science labs in India work on exactly the kind of invention that section 3(d) was written to test: a new salt that dissolves faster, a polymorph that is more stable, a co-crystal, a nanoformulation of an approved drug. These can be real advances, and some are patentable. What the Patent Office will ask is narrow and specific, and a faculty inventor who knows it before running the last set of experiments is in a much better position than one who learns it from an examination report.

What does section 3(d) say?

Section 3 of the Patents Act, 1970 lists what is not an invention. Section 3(d) excludes three things:

  1. A mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance.
  2. Any mere discovery of a new property or new use for a known substance.
  3. Mere use of a known process, machine or apparatus, unless that process results in a new product or employs at least one new reactant.

For chemists, the Explanation does the heavy lifting. Salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of a known substance are considered the same substance "unless they differ significantly in properties with regard to efficacy."

So the test has two parts. Is your compound a new form of a known substance? If yes, does it differ significantly in efficacy?

What counts as a "new form"?

Its list is long, and "other derivatives" makes it open-ended. Most of what a formulation or solid-state lab produces falls inside it.

What your lab made Treated as the same substance? What you must show
A new salt of a known active Yes, listed Significant difference in efficacy
A new polymorph or crystalline form Yes, listed Significant difference in efficacy
A single isomer from a known racemate Yes, listed Significant difference in efficacy
A known active at a new particle size Yes, listed Significant difference in efficacy
A metabolite of a known drug Yes, listed Significant difference in efficacy
An ester or ether prodrug Yes, listed Significant difference in efficacy
A genuinely new chemical entity No Novelty and inventive step, as for any invention
A combination of known actives Listed in the Explanation; section 3(e) also applies Efficacy, and more than an aggregation of known properties

Section 3(e) is the companion provision for mixtures. It excludes a substance obtained by mere admixture resulting only in the aggregation of the properties of its components. Combination products usually need to show a synergistic effect to clear it.

How an examiner reads a new-form claim under section 3(d)

1
Identify the known substanceThe nearest known form the new one derives from
2
Is the claim a new form of it?Salts, polymorphs, isomers and the rest of the list
3
Is enhanced efficacy shown?For a medicine, therapeutic efficacy
4
Is it backed by data?A comparison with the known substance
5
Then novelty and inventive stepSection 3(d) is an extra hurdle, not a substitute

What did the Supreme Court decide in Novartis?

Novartis AG v Union of India, decided by the Supreme Court on 1 April 2013, is the leading case. Novartis sought a patent on the beta crystalline form of imatinib mesylate. The Court held that the beta form failed section 3(d).

Three points from the judgment shape every pharmaceutical 3(d) objection today. I have taken the wording from the passages of the judgment quoted in a 2024 decision of the Madras High Court, which cites them by paragraph:

  • For a medicine, efficacy means therapeutic efficacy. Improvements in properties such as flow, thermodynamic stability or hygroscopicity were not shown to amount to enhanced efficacy.
  • "Just increased bioavailability alone may not necessarily lead to an enhancement of therapeutic efficacy." Whether it does "must be specifically claimed and established by research data" (paragraph 166 as cited).
  • The finding against the beta form is "not to say that Section 3 (d) bars patent protection for all incremental inventions" (paragraph 168 as cited).

That last point is the one I would underline for any researcher. Section 3(d) raises the bar for new forms. It does not close the door on them.

How the courts have applied it since

The Madras High Court decision mentioned above, Bristol Myers Squibb Company v Deputy Controller of Patents (10 July 2024), concerned a hemisulphate salt of a CGRP receptor antagonist. A Controller had rejected the application under section 3(d), and the Court set aside the order and sent it back to a different officer to reconsider whether the enhanced bioavailability shown was significant and whether it enhanced therapeutic efficacy.

For a lab, the lesson is practical. Everything turned on what the data showed, compared with the base compound, at the dose that matters. Courts and the Patent Office are still working out how much data, and of what kind, is enough, so treat any single decision as a guide and not a formula.

What efficacy data should a pharma lab generate?

Plan the comparison before you file. Proving efficacy is the applicant's burden, and the comparison must be against the known substance, not against a placebo.

Two data packages for the same new salt

Likely to struggle
Solubility and stability data only
Compared with an unrelated form
No in vivo or therapeutic endpoint
vs
Stronger under 3(d)
Compared with the known base or salt
Same dose, same model
A therapeutic endpoint, with statistics

Physico-chemical gains help the product. Therapeutic data helps the patent.

In practical terms:

  • Name the known substance you are comparing against, and choose the nearest one, usually the base compound or the marketed form.
  • Use equivalent doses, and say how you converted between forms.
  • Measure a therapeutic outcome where you can: efficacy in a validated disease model, reduced toxicity at an effective dose, or a pharmacodynamic endpoint linked to the disease.
  • If your advantage is bioavailability, add the step that links it to a therapeutic outcome.
  • Put the efficacy claim and the data in the complete specification. Further data can sometimes be filed later in reply to an objection, but the specification is where the claim should start.

Reduced toxicity as a form of enhanced efficacy is argued often and accepted case by case. I would not rely on it without in vivo data.

Timing: publication and the 3(d) data

Faculty face a timing problem. Efficacy studies take months, and the pressure to publish is constant. Publishing the form and its properties before filing can destroy novelty; published before filing explains the limited grace periods. A common route is a provisional application once the new form is characterised, then 12 months to generate the comparative efficacy data before the complete specification. From paper to patent application covers how to convert a manuscript into a specification, and a prior art search will tell you which known form you will be compared against.

New uses, processes and method of treatment

The second limb of section 3(d) excludes the mere discovery of a new use for a known substance. Section 3(i) separately excludes processes for the medicinal, surgical, curative, prophylactic or other treatment of human beings. Together they make a pure second-use claim difficult in India, even where it is available in other countries. If your work is a new use, discuss early whether there is a new formulation or product to claim alongside it.

Its third limb excludes the mere use of a known process unless it gives a new product or uses at least one new reactant. A process chemistry group with a cleaner route to a known drug should check which of those two it can show.

How this affects licensing

An industry partner will ask about section 3(d) on the first call. A licensee pays for exclusivity it can defend, and a new-form patent with thin efficacy data is easy to oppose. Faculty who arrive with a clear comparison study have a better licensing conversation, and a better case for the TRL their work has reached; TRL in drug development maps the stages.

For first-pass questions on technology transfer, TT Co-Pilot is an AI assistant built for TTO teams and faculty on Zernyx's proprietary technology licensing dataset. When you are ready to see how your technology might be applied commercially, Zernyx Hub has mapped patents from universities across India, with AI business insight on each, including commercial applications.

Common questions

Is a new salt or polymorph of a known drug patentable in India?

Only if it differs significantly in properties with regard to efficacy. The Explanation to section 3(d) treats salts, esters, ethers, polymorphs, metabolites, isomers, complexes and other derivatives of a known substance as the same substance unless they do. For a medicine, that means enhanced therapeutic efficacy, supported by data.

Is better bioavailability enough to pass section 3(d)?

Not by itself. In Novartis AG v Union of India (2013), the Supreme Court said increased bioavailability alone may not necessarily lead to enhanced therapeutic efficacy, and that whether it does must be specifically claimed and established by research data.

Does section 3(d) ban all incremental pharmaceutical inventions?

No. The Supreme Court said in Novartis that its finding against the beta crystalline form of imatinib mesylate did not mean section 3(d) bars patent protection for all incremental inventions of chemical and pharmaceutical substances.

Is a new use of a known drug patentable in India?

Section 3(d) also excludes the mere discovery of a new property or new use for a known substance. Separately, section 3(i) excludes methods of medical treatment. A new use claim on its own is therefore difficult to obtain in India.

Sahil Sheikh
About the author

Sahil Sheikh, Regd. Patent & Trademark Agent, cRTTP

Chief IP & Technology Officer, Zernyx Innovations

Connect on LinkedIn

Find a technology you can own.

Search patented technologies from Indian universities and labs, check their readiness and license the right one on Zernyx Hub.

Explore Zernyx Hub

Keep reading

Looking for something else?